-
Anti-PD-L1: Targeting Tumor Evasion with Immune Checkpoint Blockade(Post)
IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr
TIGIT: A New Frontier in Cancer and Autoimmune Disease Immunotherapy(Post)TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy and the treatment of autoimmune diseases. As a checkpoint receptor, TIGIT
Red Blood Cell Peroxidase Interference in Competitive ELISA(Post)QUICK ANSWER A researcher ran a competitive 2,3-bisphosphoglycerate (2,3-BPG) ELISA on red blood cell (RBC) lysate. The standard curve was textbook, yet every lysate sample read at the
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies(Post)1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon
Anticuerpos para IHC: cómo validarlos y evitar falsos positivos(Post)Anticuerpos para IHC: cómo validarlos y evitar falsos positivos Use anticuerpos con evidencia publicada en inmunohistoquímica y, siempre que sea posible, opte por monoclonales o recombinantes: ofrece
Cell Signalling – Mini Review(Post)Cell Signalling Cell signalling pathways have an important role in integrating a plethora of extracellular and intracellular signals to produce a controlled optimal o
Polo-like kinase (Plk1) substrates and mitosis(Post)Polo-like kinase (Plk1) Polo-like kinase (Plk1), is a serine/threonine kinase that is active during mitosis (Hamanaka et al., 1995). Its name is derived from its origi
PI3K / AKT / mTOR Signalling in T Cells(Page) Mesenchymal Stem Cell Differentiation Pathways: Unraveling Lineage-Specific Markers(Post)The intricate process of mesenchymal stem cell (MSC) differentiation is a cornerstone of developmental biology and regenerative medicine. Mesenchymal stem cells, renowned for their self-renewal ca
Th17 Cells and the IL-23 Axis(Page) Pathological functions of IL-33/ST2 in IBD and Cancer(Post)By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr
Dendritic Cells - Markers, Activation & Subtypes(Post)Immunology · Antigen PresentationDendritic Cells: Markers, Activation and SubtypesDendritic cells are the professional antigen-presenting cells that decide whether an immune response happens at all. T
Protein Kinases: Overview, Classification and Therapeutic Potential(Post)Cell Signalling · EnzymologyProtein Kinases: Function, Classification, Structure and InhibitorsProtein kinases transfer a phosphate group from ATP onto specific residues of target proteins, switching
Validated GeniePlex Panels(Page) IHC Troubleshooting Guide - Mandarin(Page)免疫组织化学(IHC)故障排除指南(中文) | Assay Genie
Unraveling the Mysteries of Platelet-Activating GPCR Signaling(Post)Platelet activation plays a pivotal role in hemostasis, the process that stops bleeding and initiates wound healing. Central to this process is the activation of G protein-coupled receptors (GPCRs
Understanding Glutamate Receptors: Classification, Function, and Implications in Neurological Disorders(Post)Glutamate receptors are pivotal in mediating excitatory neurotransmission in the central nervous system (CNS), playing crucial roles in synaptic transmission, plasticity, learning, and memory. The
Ozuriftamab: A Closer Look at This Anti-CD47 Antibody in Cancer Immunotherapy(Post)What You Need to Know About OzuriftamabWhat is Ozuriftamab?Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer c
5 Types of Immunoglobulins: IgG, IgA, IgM, IgD & IgE(Post)Immunology Guide 5 Types of Immunoglobulins: IgG, IgA, IgM, IgD & IgE The five antibody classes that drive immune defence — their structure, fun
15 Minute Qualitative COVID-19 Test | Assay Genie(Post)COVID-19 Testing Results in 15 Minutes Accurate detection of IgM and IgG patient-generated antibodies with the rapid, point